<DOC>
	<DOCNO>NCT00315705</DOCNO>
	<brief_summary>Clofarabine ( injection ) approve Food Drug Administration ( FDA ) treatment pediatric patient 1 21 year old relapse refractory acute lymphoblastic leukemia ( ALL ) least 2 prior treatment regimen . This use base induction complete response . Randomized trial demonstrate increase survival clinical benefit conduct . The purpose phase 1 portion study determine clofarabine add combination etoposide cyclophosphamide safe child relapse refractory acute lymphoblastic leukemia ( ALL ) acute myelogenous leukemia ( AML ) . The purpose phase 2 portion study measure effectiveness combination therapy child ALL .</brief_summary>
	<brief_title>A Study Clofarabine Combination With Etoposide Cyclophosphamide Children With Acute Leukemias .</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>NOTE : following eligibility criterion applicable acute lymphoblastic leukemia ( ALL ) acute myelogenous leukemia ( AML ) patient Phase 1 portion study , ALL patient Phase 2 portion study ( ALL patient allow Phase 2 portion study ) . ALL &gt; 25 % blast bone marrow ; AML ≥ 5 % blast bone marrow ; ALL AML patient may extramedullary disease Karnofsky Performance Status ≥ 50 patient &gt; 10 year old ; Lansky Performance Status ≥ 50 patient ≤ 10 year old Prior therapy : AML : 12 prior induction regimen ≤ 1 hematopoietic stem cell transplant ( HSCT ) ; ALL : 13 prior induction regimen Adequate liver , renal , pancreatic , cardiac function Have receive prior HSCT ( study amend Phase 2 exclude patient prior HSCT ) NOTE : following eligibility criterion applicable ALL AML patient Phase 1 portion study , ALL patient Phase 2 portion study ( ALL patient allow Phase 2 portion study ) . Burkitt 's leukemia Previous treatment clofarabine Uncontrolled systemic fungal , bacterial infection 48 hr negative blood culture require patient history fever within 3 day enrollment Active CNS involvement ( i.e. , CNS1 CNS2 ) Inadequate time since last therapy : ≤ 14 day since last cytotoxic chemotherapy ; ≤ 7 day since last biologic therapy ; ≤ 14 day since last monoclonal antibody therapy Have receive prior HSCT ( study amend Phase 2 exclude patient prior HSCT ) Pregnant lactate Have test positive hepatitis B hepatitis C infection history cirrhosis</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>clofarabine</keyword>
	<keyword>acute leukemia</keyword>
	<keyword>ALL</keyword>
	<keyword>AML</keyword>
	<keyword>clolar</keyword>
	<keyword>CLO218</keyword>
</DOC>